AdvtAdvtJoin the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. Download the ETPharma App and get the Realtime updates and Save your favourite articles. BioNTech countersued Moderna in February, arguing Moderna's next-generation COVID-19 shot, MNEXSPIKE, infringes one of its patents. (Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)>

Source: Economic Times March 05, 2026 02:33 UTC